Executive Briefing Series (formerly The Food & Drug Letter)
June 15, 2012
From IND to eCTD: Process Allows Data to Be Submitted as It’s Collected
Despite having an extra year before they must start submitting IND applications electronically to the FDA, companies should convert their IND process before NDAs and BLAs, in order to gain experience with smaller and less time-critical submissions.
This article is viewable by subscribers only. To view this article, please select an option below.